NasdaqGS:NBIXBiotechs
Neurocrine’s Two Year CAH Data May Reframe NBIX Valuation Story
Neurocrine Biosciences (NasdaqGS:NBIX) reported new two‑year Phase 3 data from its CAHtalyst Pediatric and Adult trials of CRENESSITY in classic congenital adrenal hyperplasia.
The peer‑reviewed results cover both children and adults and highlight durable efficacy alongside physiologic glucocorticoid dosing.
Data show sustained reductions in harmful steroid exposure and clinical improvements, including better body mass index and insulin resistance in pediatric patients.
These findings...